What is Zacks Research’s Estimate for Danaher Q2 Earnings?

Danaher Corporation (NYSE:DHR) – Research analysts at Zacks Research lifted their Q2 2026 earnings per share (EPS) estimates for Danaher in a note issued to investors on Wednesday, January 7th. Zacks Research analyst Team now expects that the conglomerate will post earnings per share of $1.93 for the quarter, up from their prior forecast of $1.92. The consensus estimate for Danaher’s current full-year earnings is $7.63 per share. Zacks Research also issued estimates for Danaher’s FY2026 earnings at $8.32 EPS.

A number of other research analysts also recently issued reports on the company. Wells Fargo & Company boosted their price objective on Danaher from $230.00 to $240.00 and gave the company an “equal weight” rating in a research note on Monday, December 15th. Morgan Stanley began coverage on Danaher in a report on Monday, December 1st. They issued an “overweight” rating and a $270.00 target price for the company. Barclays increased their price target on Danaher from $225.00 to $250.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. KeyCorp reaffirmed an “overweight” rating on shares of Danaher in a research report on Thursday, December 18th. Finally, Evercore ISI reiterated an “outperform” rating and set a $250.00 target price on shares of Danaher in a research report on Monday, January 5th. Twenty-one analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $249.92.

Danaher Stock Performance

Shares of DHR opened at $235.40 on Monday. The company has a current ratio of 1.52, a quick ratio of 1.10 and a debt-to-equity ratio of 0.33. The firm’s fifty day simple moving average is $226.70 and its two-hundred day simple moving average is $211.20. Danaher has a 12 month low of $171.00 and a 12 month high of $258.23. The stock has a market capitalization of $166.27 billion, a P/E ratio of 48.54, a price-to-earnings-growth ratio of 4.25 and a beta of 0.89.

Danaher (NYSE:DHR) last released its earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The business had revenue of $6.05 billion during the quarter, compared to the consensus estimate of $6 billion. During the same quarter in the prior year, the firm posted $1.71 EPS. The company’s revenue for the quarter was up 4.4% compared to the same quarter last year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Friday, December 26th will be issued a dividend of $0.32 per share. The ex-dividend date is Friday, December 26th. This represents a $1.28 annualized dividend and a yield of 0.5%. Danaher’s dividend payout ratio is presently 26.39%.

Insider Buying and Selling at Danaher

In other news, SVP Brian W. Ellis sold 21,776 shares of Danaher stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the completion of the transaction, the senior vice president directly owned 14,553 shares in the company, valued at $3,190,454.19. This trade represents a 59.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Teri List sold 3,298 shares of the company’s stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total transaction of $746,997.00. Following the completion of the sale, the director owned 20,762 shares in the company, valued at $4,702,593. This represents a 13.71% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 30,248 shares of company stock valued at $6,609,663. Corporate insiders own 11.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Intech Investment Management LLC lifted its position in shares of Danaher by 46.8% during the first quarter. Intech Investment Management LLC now owns 14,591 shares of the conglomerate’s stock valued at $2,991,000 after purchasing an additional 4,653 shares in the last quarter. Modern Wealth Management LLC increased its stake in Danaher by 42.7% in the 1st quarter. Modern Wealth Management LLC now owns 1,521 shares of the conglomerate’s stock valued at $312,000 after buying an additional 455 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. lifted its position in shares of Danaher by 15.0% during the 2nd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 6,802 shares of the conglomerate’s stock worth $1,344,000 after buying an additional 888 shares in the last quarter. Peak Financial Advisors LLC bought a new position in shares of Danaher during the 2nd quarter worth approximately $480,000. Finally, Capital Asset Advisory Services LLC boosted its stake in shares of Danaher by 0.7% in the 2nd quarter. Capital Asset Advisory Services LLC now owns 11,786 shares of the conglomerate’s stock worth $2,370,000 after buying an additional 77 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Key Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Management raised FY‑2025 EPS guidance to $7.80 (vs. consensus ~$7.71), signalling confidence in near‑term earnings execution — a direct driver of upside expectations for the stock.
• Positive Sentiment: Danaher said Q4 revenue is tracking at the high end of guidance on strength in bioprocessing, indicating better-than-expected top-line momentum in a core growth area. Danaher Forecasts 4Q Revenue at High-End of Guidance on Bioprocessing Strength — Update
• Positive Sentiment: Equity research support: William Blair reiterated a Buy rating, arguing Danaher’s broad-based outperformance and growth justify a premium multiple — helps underpin investor confidence. Danaher: Buy Rating Reiterated on Broad-Based Outperformance and Premium-Justified Growth Outlook
• Positive Sentiment: Fund flows/manager positioning: Mar Vista flagged Danaher as a top contributor in Q4 for its U.S. Quality strategy, signalling institutional demand from quality-oriented funds. Mar Vista U.S. Quality Q4 2025 Top Contributors And Detractors
• Neutral Sentiment: Management commentary: Danaher presented at the J.P. Morgan Healthcare Conference (transcript available) — useful for detail on strategy and outlook but largely reiterative; may not move the stock much unless new incremental news emerged. Danaher Corporation (DHR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Neutral Sentiment: CEO commentary scheduled/posted around Q4 results (PR release) — offers management color but is expected given the earnings cadence. Danaher CEO to Comment on Financial Performance
• Positive Sentiment: Zacks issued a positive estimate lift for Danaher earnings, adding analyst backing to the outlook. Zacks Research Issues Positive Estimate for Danaher Earnings
• Negative Sentiment: Insider selling flagged in recent reporting — raises near-term caution for some investors and can weigh on sentiment, particularly after a strong run-up. Possible Bearish Signals With Danaher Insiders Disposing Stock
• Negative Sentiment: High valuation (current PE ~48x) and recent gains increase the risk of profit-taking and short-term pullbacks despite positive fundamentals — likely a contributor to today’s weakness.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.